Thermi, an Almirall S.A. company, and Sinclair Pharma have mutually agreed to terminate their collaboration for the marketing of Silhouette Instalift.
Both companies have been working through a joint marketing agreement for two years. Thermi and Sinclair have decided, given the growth opportunities in this market, to focus on their own core business in order to fully leverage its potential.
Under terms of the agreement entered into in May 2016, Thermi was granted exclusive four-year distribution rights for the US market until mid-2020. The agreement involved a material investment in the launch and marketing of Silhouette Instalift by Sinclair. Almirall will receive an undisclosed consideration from Sinclair.
Thermi will continue offering the ThermiRF platform.